Skip to main navigation Skip to search Skip to main content

Early clinical markers of aggressive multiple sclerosis

  • MSBase Study Group
  • University of Melbourne, Peter MacCallum Cancer Centre
  • Royal Melbourne Hospital
  • Karolinska Institutet
  • Charles University
  • University of Bari
  • Hospital Universitario Virgen Macarena
  • IRCCS Fondazione Istituto Neurologico Casimiro Mondino - Pavia
  • Azienda Ospedaliera Universitaria
  • University of Modena and Reggio Emilia
  • University of Bologna
  • IRCCS Istituto delle Scienze Neurologiche di Bologna
  • University of Montreal
  • CISSS de Chaudière-Appalaches
  • Neuro Rive-Sud
  • Dokuz Eylul University
  • Université catholique de Louvain
  • University of Parma
  • Zuyderland
  • UOC Neurologia
  • Karadeniz Technical University
  • Université de Tunis El Manar
  • Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino
  • Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases
  • University of Copenhagen
  • Groene Hart Hospital
  • Haydarpaşa Numune Training and Research Hospital
  • Generalitat de Catalunya
  • Ondokuz Mayis University
  • Hospital Italiano de Buenos Aires
  • Flinders University
  • University of Queensland
  • Royal Brisbane and Women's Hospital
  • Austin Health
  • Universidade Metropolitana de Santos
  • Hospital Universitario Donostia
  • Koc University
  • Monash University
  • Alfred Health

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Abstract

Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) 5 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are present in the first year of disease. The development of early predictive models of aggressive multiple sclerosis is essential to optimize treatment in this multiple sclerosis subtype. We evaluated whether patients who will develop aggressive multiple sclerosis can be identified based on early clinical markers. We then replicated this analysis in an independent cohort. Patient data were obtained from the MSBase observational study. Inclusion criteria were (i) first recorded disability score (EDSS) within 12 months of symptom onset; (ii) at least two recorded EDSS scores; and (iii) at least 10 years of observation time, based on time of last recorded EDSS score. Patients were classified as having 'aggressive multiple sclerosis' if all of the following criteria were met: (i) EDSS 5 6 reached within 10 years of symptom onset; (ii) EDSS 5 6 confirmed and sustained over 56 months; and (iii) EDSS 5 6 sustained until the end of follow-up. Clinical predictors included patient variables (sex, age at onset, baseline EDSS, disease duration at first visit) and recorded relapses in the first 12 months since disease onset (count, pyramidal signs, bowel-bladder symptoms, cerebellar signs, incomplete relapse recovery, steroid administration, hospitalization). Predictors were evaluated using Bayesian model averaging. Independent validation was performed using data from the Swedish Multiple Sclerosis Registry. Of the 2403 patients identified, 145 were classified as having aggressive multiple sclerosis (6%). Bayesian model averaging identified three statistical predictors: age 4 35 at symptom onset, EDSS 5 3 in the first year, and the presence of pyramidal signs in the first year. This model significantly predicted aggressive multiple sclerosis [area under the curve (AUC) = 0.80, 95% confidence intervals (CIs): 0.75, 0.84, positive predictive value = 0.15, negative predictive value = 0.98]. The presence of all three signs was strongly predictive, with 32% of such patients meeting aggressive disease criteria. The absence of all three signs was associated with a 1.4% risk. Of the 556 eligible patients in the Swedish Multiple Sclerosis Registry cohort, 34 (6%) met criteria for aggressive multiple sclerosis. The combination of all three signs was also predictive in this cohort (AUC = 0.75, 95% CIs: 0.66, 0.84, positive predictive value = 0.15, negative predictive value = 0.97). Taken together, these findings suggest that older age at symptom onset, greater disability during the first year, and pyramidal signs in the first year are early indicators of aggressive multiple sclerosis.

Original languageEnglish
Pages (from-to)1400-1413
Number of pages14
JournalBrain
Volume143
Issue number5
DOIs
Publication statusPublished - 1 May 2020

Keywords

  • Aggressive disease
  • Disability
  • Multiple sclerosis
  • Precision medicine
  • Prediction

Fingerprint

Dive into the research topics of 'Early clinical markers of aggressive multiple sclerosis'. Together they form a unique fingerprint.

Cite this